RxDoctor Payments DataLook up a doctor →

David Kuter, MD

Hematology · Boston, MANPI 1457342024

Payments from drug & device makers

$3,102,430in general payments, 2019–2025

Across 522 payments — averaging $5943.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1M
  • Agios Pharmaceuticals, Inc.$460K
  • Sanofi US Services Inc.$384K
  • Sanofi$256K
  • Bioverativ Therapeutics Inc.$147K
  • Amgen$129K
  • plus $706K from 26 others
$299,913in research payments, 2019–2025

Across 74 payments — averaging $4052.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Rigel Pharmaceuticals, Inc.$242K
  • Amgen$26K
  • Sanofi$14K
  • Bioverativ Therapeutics Inc.$6K
  • Novartis$4K
  • Novartis Pharma AG$4K
  • plus $4K from 4 others

What the payments were for

  • Consulting fees$369,88068%
  • Speaking & faculty fees$83,83315%
  • Travel & lodging$84,92216%
  • Food & beverage$4,2321%
  • Education$420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,102,430 in reported general payments places this provider in the 90th percentile of 77 hematology providers in Massachusetts.

See all hematology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$95,458
Medicare patients
350
Services billed
1,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate123$1,936,630
CerdelgaEliglustat Tartrate16$493,281
DopteletAvatrombopag Maleate23$429,720
ImbruvicaIbrutinib34$419,597
EliquisApixaban96$129,876
XareltoRivaroxaban72$95,830
RetacritEpoetin Alfa-Epbx12$41,193
Fondaparinux Sodium19$24,697
Hydroxyurea135$4,647
Prednisone27$444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$66,715$1,936,630123 claims
SanofiCerdelga$256,078$493,28116 claims
Dova PharmaceuticalsDoptelet$26,547$429,72023 claims
PfizerEliquis, Retacrit$4,500$171,070108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 77 hematology providers in Massachusetts.

Other hematology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →